depression, Major Depressive Disorder depression
Conditions
Interventions
Three six-week interventions (VBA-MIE, VBA, BA) will be implemented. Participants will be randomly assigned (1:1:1) and receive two on-site group training sessions plus four online individual check-in
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Participants should be between 18 and 67 years old; Participants possess sufficient cognitive abilities to participate adequately in the study (IQ >85 on the Dutch Adult Reading Test (DART) and/or having finished at least vocational education level); Participants should show sufficient fluency in Dutch; Participants should be able to participate in the study (sufficient smartphone use, no subjective neurological complaints, sufficient physical condition for study participation); Main inclusion criteria for remitted depressed individuals: Participants should be in remission from a Major Depressive Episode for more than two months, defined by the criteria of the Diagnostic Statistical Manual, version 5; Participants should have experienced at least one Depressive episode experienced in the past two years and be in remission for at least two months;Patients should score 25 or lower on the Inventory of Depressive Symptomatology (IDS-SR30), indicative of the absence of clinically relevant depressive symptoms.
Exclusion criteria
Exclusion criteria: Main exclusion criteria for the remitted depressed group:Participants who meet the criteria for a current bipolar, autism, ADHD/ADD, psychosis, anxiety, schizophrenia, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), feeding and eating disorder, or substance-related or addictive disorder diagnoses as objectified with the SCID-5;Participants who recently received protocolized BA therapy (defined as during their last episode, or as one year prior to inclusion in case the last episode was more than a year before inclusion); Daily use of medication that affects the dopamine system (such as MAO-inhibitors, bupropion, etc.) currently or in the last four weeks.Main exclusion criteria for the never-depressed group: Presence of symptoms of depression according to the IDS-SR30 (score < 14); Any life-time psychopathology of any disorder as objectified with the SCID-5.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcomes include pre- vs. post-intervention changes in daily functioning (measured with questionnaires). The neuroimaging study will evaluate the impact of reward magnitude on cognitive control performance and its temporal variation (measured with a control-for-reward task) between rMDD and ND individuals. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome measures include pre- vs. post-intervention changes in outcomes of daily life functioning (i.e., activity patterns, social functioning), cognitive control performance, parameters underlying cognitive control allocation (i.e., reward value, perceived controllability, and perceived effort), depressive (residual) symptoms, other psychological factors associated with depressive vulnerability, and relapse risk. Secondary outcomes measures of the neuroimaging study include differences in activity of brain regions associated with reward processing (MID task), structural difference in the brain's reward system (measured with NM-sensitive MRI) and behavioural performance on the MID task between rMDD and ND individuals during the MID task. | — |
Countries
Netherlands
Contacts
Public ContactM.J. Tol
Universitair Medisch Centrum Groningen
Outcome results
None listed